GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory
system have been largely investigated, scanty controlled data are available concerning the
role of dietary and metabolic approaches in the management/outcome of patients with heart
failure. A large scale, randomized, clinical trial is proposed to test the effects of (a) n-3
PUFA and (b) a lipid lowering agent on top of the best recommended treatments for heart
failure.
STUDY DESIGN
The GISSI-HF is a prospective, multicenter, randomized, double blind, placebo controlled
study, with randomized allocation of patients with a clinical diagnosis of heart failure to:
Randomization 1 (R1): n-3 PUFA 1 g daily vs corresponding placebo; Randomization 2 (R2):
rosuvastatin 10 mg daily vs corresponding placebo.
OBJECTIVES OF THE STUDY PRIMARY OBJECTIVES
To demonstrate that, in patients with heart failure treated at the best of recommended
therapies, long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than
the corresponding placebo in the reduction of:
- All-cause mortality
- All-cause mortality or hospitalizations for cardiovascular reason
OTHER END-POINT MEASURES OF EFFICACY
To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective
than corresponding placebo in the reduction of:
- Cardiovascular mortality
- Cardiovascular mortality or hospitalizations for any reason
- Sudden cardiac death
- Hospitalizations for any reason
- Hospitalizations for cardiovascular reasons
- Hospitalizations for congestive heart failure
- Myocardial infarction
- Stroke